Lanabecestat
- Generic Name
- Lanabecestat
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28N4O
- CAS Number
- 1383982-64-6
- Unique Ingredient Identifier
- X8SPJ492VF
- Background
Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03545087
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Ctr., Orlando, Florida, United States
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03506399
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study of LY3314814 in Participants With Liver Impairment
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03499041
- Locations
- 🇺🇸
New Orleans Cntr for Clin Res, Knoxville, Tennessee, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of LY3314814 in Healthy Participants
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT03222427
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT03019549
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 421
- Registration Number
- NCT02972658
- Locations
- 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸IMIC, Inc., Palmetto Bay, Florida, United States
🇺🇸Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1722
- Registration Number
- NCT02783573
- Locations
- 🇺🇸
Maine Neurology, Scarborough, Maine, United States
🇺🇸Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Atlanta Center of Medical Research, Atlanta, Georgia, United States
A Study of Lanabecestat (LY3314814) in Healthy Participants
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT02663128
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT02568397
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT02540668
- Locations
- 🇺🇸
Covance Clinical Research Inc, Evansville, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.